As Philips reaches a consent decree agreement with the FDA that will temporarily suspend its sales of sleep therapy devices in the U.S., competitor ResMed, meanwhile, is ramping up its product ...

On Thursday, ResMed Inc (NYSE:RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating ...

ResMed, Inc. RMD recently introduced its AirCurve 11 series devices. These are the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure and expiratory ...

ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

July 31 (Reuters) - Resmed (RMD.N), opens new tab beat Wall Street estimates for fourth-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea. The company ...

San Diego, California-based ResMed has received FDA 510(k) clearance for its small, portable continuous positive airway pressure (CPAP) device, the AirMini. The announcement was made during the JP ...

Local medical device maker ResMed is adjusting its executive leadership assignments and cutting back its workforce to accommodate a shift in strategy. The San Diego-based company is pushing to improve ...

Needham upgraded ResMed Inc RMD from a Hold to Buy rating with a price target of $180. The analysts Mike Matson, Joseph Conway, and David Saxon note that ResMed's shares are down 31% since the start ...

Coronavirus continues to suppress sleep apnea diagnosis rates and hence Resmed’s sleep device sales in third-quarter fiscal 2021, but still broadly track our full-year expectations for a ...

Oct 24 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment. Shares of the ...